Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on Top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk

NCT07614958 is registered in ClinicalTrials.gov with A. Menarini International Licensing S.A. as lead sponsor.

NCT NCT07614958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07614958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on Top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk
Lead sponsor
A. Menarini International Licensing S.A.
Phase
Phase 3
Overall status
Recruiting
Start date
May 6, 2026
Completion date
January 31, 2027
Enrollment
426 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolaemia, mixed dyslipidemia